3
Dec
2014
Top 10 biologic sales & Growth Y/Y – 2012/2013
Worldwide Top 1o Biologic sales
| Ranking 2013 | Ranking 2012 | Brand | Lead company | Molecule type | Approved indication(s) | 2012 Sale in Billion | 2013 Sale in Billion | % Change |
| 1 | 1 | Humira (adalimumab) | AbbVie | mAb | Rheumatoid arthritis (RA), juvenile rheumatoid arthritis, Crohn’s disease, psoriatic arthritis (PA), psoriasis, ankylosing spondylitis, ulcerative colitis (UC), Behçet syndrome | 9.3 | 10.7 | 15.5 |
| 2 | 2 | Remicade (infliximab) | J&J | mAb | RA, Crohn’s disease, psoriasis, UC, ankylosing spondylitis, Behçet syndrome, PA | 6.6 | 8.9 | 35.6 |
| 3 | 3 | Enbrel (etanercept) | Amgen | Protein | RA, psoriasis, ankylosing spondylitis, PA, juvenile rheumatoid arthritis | 8.0 | 8.3 | 4.2 |
| 4 | Lantus | Sanofi | Insulin glargine | Diabetes | 7.6 | NA | ||
| 5 | 4 | Rituxan (rituximab) | Roche | mAb | RA, chronic lymphocytic leukemia/small cell lymphocytic lymphoma, non-Hodgkin’s lymphoma, antineutrophil cytoplasmic antibodies associated vasculitis, indolent non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma | 7.0 | 7.4 | 5.0 |
| 6 | 5 | Avastin (bevacizumab) | Roche | mAb | Colorectal cancer, non–small cell lung cancer, renal cell cancer, brain cancer (malignant glioma; anaplastic astrocytoma, glioblastoma multiforme) | 6.1 | 6.7 | 10.6 |
| 7 | 6 | Herceptin (trastuzumab) | Roche | mAb | Breast cancer, gastric cancer | 6.2 | 6.6 | 6.7 |
| 8 | 7 | Neulasta (pegfilgrastim) | Amgen | Protein | Neutropenia/leukopenia | 4.1 | 4.4 | 7.5 |
| 9 | 8 | Lucentis (ranibizumab) | Roche | mAb | Wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion | 4.0 | 4.2 | 4.9 |
| 10 | 9 | Avonex (interferon beta-1a) | Biogen IDEC | Protein | Multiple sclerosis | 2.9 | 3 | 3.0 |
| 10 | Rebif (interferon beta-1a) | Merck | Protein | Multiple sclerosis | 2.4 | NA |
Related Articles
About Post Author
